U.S.S.N. 10/567.021 Applicants: Lange et al.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-7. (Canceled)

11.

- 8. (Previously Presented) A method comprising performing density gradient centrifugation on bone marrow; and isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml.
- 9. (Currently Amended) The method according to claim [[1]]8, wherein said performing uses an isotonic solution of Ficoll® or Percoll®.
- 10. (Currently Amended) The method according to claim [[2]]9, wherein said isotonic solution is Percoll® and said density is 1.068 g/ml.
- (Currently Amended) A mesenchymal stem cell obtained according to a method of claim 8 comprising performing density gradient centrifugation on bone marrow; and isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml.
- 12 (Currently Amended) [[A]] The mesenchymal stem cell obtained according to a method of claim [[9]111] wherein said performing uses an isotonic solution of Ficoll® or Percoll®.
- 13. (Currently Amended) [[A]] The mesenchymal stem cell obtained according to a method of claim [[10]]12 wherein said isotonic solution is Percoll® and said density is 1.068 g/ml.
- 14 (Currently Amended) A pharmaceutical preparation comprising a mesenchymal stem cell obtained according to a method comprising performing density gradient centrifugation on bone marrow; and

U.S.S.N. 10/567,021 Applicants: Lange et al.

isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml according to claim 11.

- (Currently Amended) [[A]] The pharmaceutical preparation comprising a mesenchymal stem cell according to of claim [[12]]14 wherein said performing uses an isotonic solution of Ficoll® or Percoll®.
- (Currently Amended) [[A]] The pharmaceutical preparation comprising a mesenchymal stem cell-according to of claim [[13]]15 wherein said isotonic solution is Percoll® and said density is 1.068 g/ml.
- (Currently Amended) A method of manufacturing a The pharmaceutical preparation of claim 14 further comprising formulating isolated mesenehymal stem cells according to claim 1 and a pharmaceutically acceptable excipient and/or carrier.
- (Currently Amended) A method of manufacturing a The pharmaceutical preparation of claim 15 further comprising formulating isolated mesenehymal stem cells according to claim 2 and a pharmaceutically acceptable excipient and/or carrier.
- (Currently Amended) A method of manufacturing a The pharmaceutical preparation of claim 16 further comprising formulating isolated mesenchymal stem cells according to claim 3 and a pharmaceutically acceptable excipient and/or carrier.
- (Previously Presented) A method of isolating mesenchymal stem cells from bone marrow
 comprising performing density gradient centrifugation using a solution of Ficoll® or Percoll®
 with a density of 1.068 g/ml.